GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta®
GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE).
Original Source of GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta®
